Compare AbCellera Biologics Inc (ABCL) vs Google Inc (GOOG) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

GOOG trades at $363.62, up 2.09% today, reflecting strong momentum after consecutive earnings beats. The stock shows a bullish technical trend with support at $358 and resistance at $369. Revenue grew to $402.84B in 2025, with net income reaching $132.17B, driven by robust profitability margins. Recent news highlights Google's AI advancements and a dividend payment, reinforcing investor confidence.

Outlook remains positive with a consensus price target of $457.50, indicating 26% upside. Risks include competitive pressures in AI and regulatory scrutiny. Analyst sentiment is overwhelmingly bullish (86.84% buy ratings), supported by strong cash flow growth and strategic investments in fusion technology and AI infrastructure.